

May 26, 2017

Achaogen Announces Multiple Plazomicin Presentations at ASM Microbe 2017 Annual Meeting

- Two oral presentations highlighting data from plazomicin Phase 3 EPIC and CARE clinical trials -

- Eleven poster presentations highlighting plazomicin's activity against MDR *Enterobacteriaceae*, including carbapenem-resistant *Enterobacteriaceae* (CRE) -

SOUTH SAN FRANCISCO, Calif., May 26, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multidrug-resistant (MDR) gram-negative infections, today announced 13 upcoming presentations on plazomicin at the American Society for Microbiology (ASM) Microbe 2017 Annual Meeting. The Company and its collaborators will deliver two oral presentations and 11 poster presentations at the event, which will be held in New Orleans, LA from June 1 to 5, 2017. Achaogen is developing plazomicin, its lead product candidate, to treat serious bacterial infections due to MDR *Enterobacteriaceae*, including carbapenem-resistant *Enterobacteriaceae* (CRE).

Oral Presentations

Title: Evaluating Once-Daily Plazomicin versus Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP): Results from a Phase 3 Study (EPIC)
 Authors: D.Cloutier (presenter), L.Miller, A.Komirenko, D.Cebrik, T.Keepers, K.Krause, L.Connolly, F.Wagenlehner
 Session: Urinary Tract Infections: New Concepts
 Sunday, June 4, 2017, 4:45 - 5:00pm ET

Title: Plazomicin (PLZ) Associated with Improved Survival and Safety Compared to Colistin (CST) in Serious Carbapenem-Resistant *Enterobacteriaceae* (CRE) Infections: Results of the CARE Study
 Authors: G.Daikos, L.Connolly (presenter), A.Jubb, B.O'Keeffe, A.Serio, A.Smith, J.Gall, K.Krause, J.McKinnell, E.Zakynthinos, V.Riddle
 Session: Development of New Drugs and Strategies for Hospital-acquired Pneumonia Caused by MDR Pathogens
 Saturday, June 3, 2017, 4:45 - 5:00pm ET

Key Poster Presentations

Title: *In Vitro* Activity of Plazomicin and Comparator Agents against Urinary Tract Infection Isolates from the United States and Europe
 Authors: M. Castanheira, T.Doyle, A.Serio, K.Krause, J.Streit, R.Flamm
 Session: 335 - AAID - Design, Evaluation, Combination and Antibacterial Activity of New Drugs, Sunday, June 4, 2017, 12:15 - 2:15pm ET

Title: Aminoglycoside-Resistant Genes among 2014-2015 US Carbapenem-Resistant *Enterobacteriaceae* Isolates and Activity of Plazomicin against Characterized Isolates
 Authors: M. Castanheira, L.Woosley, T.Doyle, A.Serio, K.Krause, R.Flamm
 Session: 335 - AAID - Design, Evaluation, Combination and Antibacterial Activity of New Drugs, Sunday, June 4, 2017, 12:15 - 2:15pm ET

Additional Poster Presentations

Title: Impact of Changes in Growth Medium, Inoculum Density and Incubation Conditions on the *In Vitro* Antimicrobial Activity of Plazomicin (Poster #410)
 Authors: L.Duncan, P.Rhomberg, B.Schaefer, R.Flamm, A.Serio, K.Krause, M.Castanheira
 Session: Session 057 - CPHM02 - Antimicrobial Susceptibility Testing I
 Friday, June 2, 2017, 12:45 - 2:45pm ET

Title: Comparison of Agar Dilution and Broth Microdilution Plazomicin MICs (Poster #416)
 Authors: M. Hackel, A.Serio, K.Krause, D. Sahn
 Session: Session 205 - CPHM02 - Antimicrobial Susceptibility Testing II
 Saturday June 3, 2017, 12:15 - 2:15pm ET

Title: Antimicrobial Activity of Plazomicin against *Enterobacteriaceae* Producing Carbapenemases from 50 Brazilian Medical Centers (Poster #2)

Authors: A.Martins, F.Tuon, L.Bail, C.Ito, J.Rocha, A.Serio, T.Dalmolin

Session: 335 - AAID - Design, Evaluation, Combination and Antibacterial Activity of New Drugs, Sunday, June 4, 2017, 12:15 - 2:15pm ET

Title: In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Pathogens Isolated from Patients in Canadian Hospitals in 2011-2015: CANWARD Surveillance Study (Poster #3)

Authors: G.Zhanel, H.Adam, M.Baxter, A.Denisuik, A.Walkty, P.Lagace-Wiens, F.Schweizer, D.Hoban, J.Karlowsky

Session: 335 - AAID - Design, Evaluation, Combination and Antibacterial Activity of New Drugs, Sunday, June 4, 2017, 12:15 - 2:15pm ET

Title: In Vitro Activity of Plazomicin (PLZ) and Comparators against Facultative Anaerobes Incubated Aerobically and Anaerobically and Obligate Anaerobes (Poster #333)

Authors: D.Citron, K.Tyrrell, E.Leoncio, A.Serio, K.Krause, E.Goldstein

Session: 351 - AAID11 - New Antimicrobial Agents: New Antibacterial Agents II
Sunday, June 4, 2017, 12:15 - 2:15pm ET

Title: Investigating the Post-Antibiotic Effect of Plazomicin against Multidrug Resistant *Enterobacteriaceae* (Poster #205)

Authors: D.Hall, M.Thwaites, D.Shinabarger, A.Serio, K.Krause, C.Pillar

Session: 341 - AAID03 - Antimicrobial Pharmacokinetics: PK/PD of New Antimicrobial Agents, Sunday, June 4, 2017, 12:15 - 2:15pm ET

Title: Pharmacokinetics (PK) of Plazomicin in Healthy Adults (Poster #206)

Authors: J.Seroogy, T.Choi, J.Gall, S.Van Wart, S.Dhuria

Session: 341 - AAID03 - Antimicrobial Pharmacokinetics: PK/PD of New Antimicrobial Agents, Sunday, June 4, 2017, 12:15 - 2:15pm ET

Title: The Pharmacodynamics (PD) of Plazomicin (PLZ) and Amikacin (AMK) against *Enterobacteriaceae* Studied in an *In Vitro* Pharmacokinetic (PK) Model of Infection (Poster #203)

Authors: K.Bowker, A.Noel, M.Attwood, S.Tomaselli, A.MacGowan, A.Kim, K.Krause

Session: 341 - AAID03 - Antimicrobial Pharmacokinetics: PK/PD of New Antimicrobial Agents, Sunday, June 4, 2017, 12:15 - 2:15pm ET

Title: Tissue Distribution of [¹⁴C]-Plazomicin in Rats (Poster #204)

Authors: T.Choi, J.Seroogy, H.Patel

Session: 341 - AAID03 - Antimicrobial Pharmacokinetics: PK/PD of New Antimicrobial Agents, Sunday, June 4, 2017, 12:15 - 2:15pm ET

The abstracts can be accessed through the [ASM Microbe website](#). Following the meeting, the presentation slides and posters will be available on the [Achaogen website](#).

About Achaogen

Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen's lead product candidate, for the treatment of serious bacterial infections due to MDR *Enterobacteriaceae*, including carbapenem-resistant *Enterobacteriaceae*. The U.S. Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections (BSI) caused by certain *Enterobacteriaceae* in patients who have limited or no alternative treatment options. Achaogen's plazomicin program is funded in part with Federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201000046C. Plazomicin is the first clinical candidate from Achaogen's gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. All product candidates are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Achaogen's expectations regarding potential regulatory approval of plazomicin, Achaogen's commercial objectives and Achaogen's pipeline of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Achaogen's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the preclinical and clinical development process; the risks and uncertainties of the regulatory approval process; the risks and uncertainties of commercialization and gaining market acceptance; the risk when bacteria will evolve resistance to plazomicin; Achaogen's reliance on third-party contract manufacturing organizations to manufacture and supply its product candidates and certain raw materials used in the

production thereof; risk of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Achaogen's patents or proprietary rights; and the risk that Achaogen's proprietary rights may be insufficient to protect its technologies and product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward- looking statements, as well as risks relating to Achaogen's business in general, see Achaogen's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed on March 14, 2017. Achaogen does not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.

Source: Achaogen, Inc.
AKAO-G

Investor Contact:
Hans Vitzthum
212.915.2568
hans@lifesciadvisors.com

Media Contact:
Denise Powell
510.703.9491
denise@redhousecomms.com